# **Stratified Medicine:** Misunderstandings and Misconceptions

## Gordon D Murray University of Edinburgh Scotland, UK



Edinburgh Hub

• Stratified medicine is a new idea

• Stratified medicine is a new idea

See, for example, Rothwell PM and Warlow CP, on behalf of the European Carotid Surgery Trialists' Collaborative Group. "Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study". *Lancet* 1999;<u>353</u>:2105-10.

#### **Overall trial results** (survival free of major stroke)



#### **Stratified trial results**



- Stratified medicine is a new idea
- Stratified medicine is all about identifying a high risk, high response subgroup (so that trials can have small sample sizes, reducing the development time, etc)

 Clinical background: patients with a high risk of developing colonic polyps (and ultimately cancer)

- Clinical background: patients with a high risk of developing colonic polyps (and ultimately cancer)
- Current management: annual colonoscopy

- Clinical background: patients with a high risk of developing colonic polyps (and ultimately cancer)
- Current management: annual colonoscopy
- Proposal: develop biomarker to identify high risk subgroup; within high risk subgroup (~20%?), run RCT of annual colonoscopy versus definitive surgery; switch low risk subgroup to colonoscopy every three years

- Stratified medicine is a new idea
- Stratified medicine is all about identifying a high risk, high response subgroup (so that trials can have small sample sizes, reducing the development time, etc)
- As long as a stratified medicine trial is 'well' designed, there is no need for a sense check

 Clinical background: patients with mild depression respond well to placebo (30% achieve remission) but respond better to SSRIs (60% achieve remission).

- Clinical background: patients with mild depression respond well to placebo (30% achieve remission) but respond better to SSRIs (60% achieve remission).
- Hypothesis: a complex marker relating to nerve conductance will identify a high response subgroup (25% of all patients, with 90% responding to SSRIs), with only 50% of the 'marker negative' patients responding to SSRIs.

- Clinical background: patients with mild depression respond well to placebo (30% achieve remission) but respond better to SSRIs (60% achieve remission).
- Hypothesis: a complex marker relating to nerve conductance will identify a high response subgroup (25% of all patients, with 90% responding to SSRIs), with only 50% of the 'marker negative' patients responding to SSRIs.
- Proposal: run a stratified RCT, powered to be able to detect this treatment/marker interaction.

• Stratified/personalised medicine is as old as medicine itself.

- Stratified/personalised medicine is as old as medicine itself.
- Funders are increasingly recognising the need to bridge the gap between trials which show that interventions work 'on average' and evidence-based decisions at the level of individual patients.

- Stratified/personalised medicine is as old as medicine itself.
- Funders are increasingly recognising the need to bridge the gap between trials which show that interventions work 'on average' and evidence-based decisions at the level of individual patients.
- Stratified medicine trials need expert statistical input.

- Stratified/personalised medicine is as old as medicine itself.
- Funders are increasingly recognising the need to bridge the gap between trials which show that interventions work 'on average' and evidence-based decisions at the level of individual patients.
- Stratified medicine trials need expert statistical input.
- Even more so than for conventional trials, stratified medicine trials need close collaboration between clinicians and methodologists.